Development of a gas chromatographic/mass spectrometric method to quantify R(-)-apomorphine, R(-)-apocodeine and R(-)-norapomorphine in human plasma and urine

Journal of Mass Spectrometry

Volumn 40, Issue 12, 2005, Pages 1521-1525

  Libert, Frédéric ^a   Coudoré, François ^a   Richard, Damien ^a   Durif, Franck ^a   Eschalier, Alain ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

Author keywords

Apomorphine; Entacapone; GC MC; Metabolism; Pharmacokinetics

Indexed keywords

AMINES; CELLS; CONCENTRATION (PROCESS); DERIVATIVES; GAS CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLISM; PHARMACOKINETICS;

APOMORPHINE; ENTACAPONE; GC/MC; HUMAN URINE;

BODY FLUIDS;

APOCODEINE; APOMORPHINE; CATECHOL METHYLTRANSFERASE INHIBITOR; ENTACAPONE; NORAPOMORPHINE; PROPYLNORAPOMORPHINE;

ACCURACY; CONFERENCE PAPER; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG STRUCTURE; DRUG URINE LEVEL; GAS CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; MASS SPECTROMETRY; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ASSAY; SILYLATION;

APOMORPHINE; CATECHOL O-METHYLTRANSFERASE; CATECHOLS; GAS CHROMATOGRAPHY-MASS SPECTROMETRY; HUMANS; PARKINSON DISEASE; REPRODUCIBILITY OF RESULTS;

EID: 30044437298     PISSN: 10765174     EISSN: None     Source Type: Journal    
DOI: 10.1002/jms.939     Document Type: Conference Paper

References (17)

1. Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J. Neurol. Neurosurg. Psychiatr. 1998; 65: 709.
2. Deleu D, Northway MG, Hanssens Y. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease. Clin. Pharmacokinet. 2002; 41: 261.
3. Neef C, van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin. Pharmacokinet. 1999; 37: 257.
4. LeWitt PA. Subcutaneously administered apomorphine: pharmacokinetics and metabolism. Neurology 2004; 62: S8.
5. Van der Geest R, Kruger P, Gubbens-Stibbe JM, van Laar T, Boddé HE, Danhof M. Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease. J. Chromatogr. B 1997; 702: 131.
6. Coudoré F, Durif F, Duroux E, Eschalier A, Fialip J. Effect of tolcapone on plasma and striatal apomorphine disposition in rats. Neuroreport 1997; 8: 877.
7. Priston MJ, Sewell GJ. Novel liquid chromatographic assay for the low-level determination of apomorphine in plasma. J. Chromatogr. B 1996; 681: 161.
8. Nicolle E, Pollack P, Serre-Debeauvais F, Richard P, Gervasson CL, Broussolle E, Gavend M. Pharmacokinetics of apomorphine in parkinsonian patients. Fundam. Clin. Pharmacol. 1993; 7: 245.
9. Sam E, Augustijns P, Verbeke N. Stability of apomorphine in plasma and its determination by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B 1994; 658: 311.
10. Bolner A, Barbato L, Tagliaro F, Monge A, Stocchi F, Nordera G. Determination of apomorphine in human plasma by alumina extraction and high-performance liquid chromatography with electrochemical detection. Forensic Sci. Int. 1997; 89: 81.
11. Bianchi G, Landi M. Determination of apomorphine in rat plasma and brain by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. 1985; 338: 230.
12. Eriksson BM, Persson BA, Lindberg M. Determination of apomorphine in plasma and brain tissue by ion-pair extraction and liquid chromatography. J. Chromatogr. B 1979; 185: 575.
13. Baaske DM, Keiser JE, Smith RV. Gas chromatographic determination of apomorphine in plasma. J. Chromatogr. B 1977; 140: 57.
14. Watanabe H, Nakano S, Ogawa N, Suzuki T. Determination of apomorphine in plasma by selected ion monitoring. Biomed. Mass Spectrom. 1980; 7: 160.
15. Green JF, Evans JV, Neumeyer JL, Vouros P. Aporphines. 25-trimethylislyl derivatives of N-methyl and N-propyl aporphines: gas chromatographic and mass spectrometric properties. Biomed. Mass Spectrom. 1979; 6: 282.
16. Neumeyer JL, Abdel-Maksoud HM, Trainor TM, Vouros P, Davis PJ. Aporphines 65: chemical, microbial synthesis and characterization by gas chromatography/mass spectrometry of (R)-(-)-10-hydroxy 11-methoxy-N-n- propylnoraporphine, a potential metabolite of N-n-propylnorapomorphine. Environ. Mass Spectrom. 1986; 13: 223.
17. Danhof M, Van der Geest R, Van Laar T, Boddé HE. An integrated pharmacokinetic-pharmacodynamic approach to optimization of R-apomorphine delivery in Parkinson's disease. Adv. Drug Deliv. Rev. 1998; 33: 253.